Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ORAL DOLASETRON MESYLATE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Autore:
DIEMUNSCH P; KORTTILA K; LEESER J; HELMERS JHJH; WILKEY B; NAVE S; RADKE AJ; HAHNE WF; BROWN RA;
Indirizzi:
HOP UNIV STRASBOURG,EXPT ANESTHESIOL UNIT,DEPT ANESTHESIOL,1 PL HOP F-67091 STRASBOURG FRANCE
Titolo Testata:
Journal of clinical anesthesia
fascicolo: 2, volume: 10, anno: 1998,
pagine: 145 - 152
SICI:
0952-8180(1998)10:2<145:ODMFPO>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGICAL SURGERY; ANTIEMETIC EFFICACY; INDUCED EMESIS; ONDANSETRON; DROPERIDOL; CHEMOTHERAPY; ANTAGONIST; ANESTHESIA; ETIOLOGY;
Keywords:
ANTIEMETICS; DOLASETRON MESYLATE; NAUSEA AND VOMITING, POSTOPERATIVE; SURGERY, GYNECOLOGIC;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
P. Diemunsch et al., "ORAL DOLASETRON MESYLATE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY", Journal of clinical anesthesia, 10(2), 1998, pp. 145-152

Abstract

Study Objective: To examine the safety and effectiveness of a range of single oral doses of dolasetron mesylate for the prevention of postoperative nausea and vomiting. Design: Randomized, double-blind, placebo-controlled trial. Setting: 32 hospital. Patients: 789 female ASA physical status I, II, and III patients, ages 18 to 60 years, weighing between 45 and 100 hg, scheduled for major gynecologic surgery (including abdominal hysterectomy, gynecologic laparotomy, or vaginal hysterectomy) with general anesthesia. Interventions: 25, 50, 100, or 200 mg oral doses of dolasetron mesylate or placebo were administered 1 to 2 hours before induction of anesthesia. Efficacy was assessed for 24 hourspostrecovery by measuring complete response (no emetic episodes, no rescue medication), total response (complete response with no nausea), time to first emetic episode or rescue and patient visual analog scaleevaluations of nausea severity and satisfaction with antiemetic therapy. Measurements and Main Results: Complete response rates for the 50,100, and 200 mg dose groups were statistically greater than placebo (p less than or equal to 0.018). Likewise, total response rates were statistically greater in the 50, 200, and 200 mg dose groups than in theplacebo group (p = 0.012). Percentage of patients with no nausea and patient satisfaction scores were significantly higher for each dolasetron dose group than placebo (p less than or equal to 0.047 and p less than or equal to 0.004, respectively). Efficacy peaked at the 50 mg dose. The incidence of adverse events was similar in the placebo (30.1%)and dolasetron groups (29.4%). Headache was the most frequent treatment-related adverse event, with 2% to 5% incidence across groups. Incidence of adverse events did not increase with increasing dolasetron doses. Dose-related decreases in blood pressure at acute time points werenot clinically significant. Conclusion: Single oral doses of dolasetron, administered 1 to 2 hours before induction of anesthesia, are safeand effective for preventing postoperative nausea and vomiting in this patient sample. Maximal antiemetic response runs seen with the 50 mgoral dolasetron dose. (C) 1998 by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 04:01:31